Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 1:00–2:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic
breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2019—DiaSorin Molecular received the CE mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic test enables the direct detection of varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens. The assay is used with the Liaison MDX instrument and complements the company’s Simplexa HSV 1 & 2 Direct kit. DiaSorin has submitted the Simplexa VZV Swab assay to the FDA for 510(k) clearance.
DiaSorin Molecular, 562-240-6500
